1. Home
  2. ANPA vs AARD Comparison

ANPA vs AARD Comparison

Compare ANPA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANPA

Rich Sparkle Holdings Limited Ordinary Shares

HOLD

Current Price

$4.60

Market Cap

103.7M

Sector

N/A

ML Signal

HOLD

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

HOLD

Current Price

$3.93

Market Cap

85.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANPA
AARD
Founded
2016
2017
Country
Hong Kong
United States
Employees
32
40
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.7M
85.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ANPA
AARD
Price
$4.60
$3.93
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$15.29
AVG Volume (30 Days)
5.4K
127.2K
Earning Date
02-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$3.35
52 Week High
$180.64
$17.94

Technical Indicators

Market Signals
Indicator
ANPA
AARD
Relative Strength Index (RSI) 28.49 44.36
Support Level N/A $3.38
Resistance Level $6.46 $4.39
Average True Range (ATR) 0.50 0.29
MACD -0.06 0.06
Stochastic Oscillator 4.02 72.22

Price Performance

Historical Comparison
ANPA
AARD

About ANPA Rich Sparkle Holdings Limited Ordinary Shares

Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: